Kadderum (Eltrombopag)

Eltrombopag activates the thrombopoietin receptor (c‑Mpl) on megakaryocyte precursors, initiating intracellular signaling that drives megakaryocyte proliferation and differentiation, ultimately raising platelet counts in the bloodstream.

The dosage of Kadderum is individualized; a qualified prescriber determines the appropriate strength and schedule based on the patient’s condition, laboratory values, and response to therapy.

Safety data for eltrombopag in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kadderum, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative is romiplostim, another thrombopoietin receptor agonist administered by injection. Kadderum offers an oral formulation, which may be preferred for convenience, whereas romiplostim requires subcutaneous dosing. Both aim to raise platelet counts, but their pharmacokinetics and administration routes differ.

Kadderum tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep out of reach of children and do not use after the expiry date.

Kadderum is taken orally with a glass of water, usually on an empty stomach to improve absorption. The tablet should be swallowed whole; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include hepatotoxicity, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function abnormalities and signs of abnormal clotting.

Kadderum is contraindicated in patients with known hypersensitivity to eltrombopag or any tablet excipients, and it should be avoided in individuals with active uncontrolled thrombotic disorders. Caution is also advised for patients with severe liver impairment.